EPISODE · May 20, 2026 · 47 MIN
Strategy& Insider Episode 46 - Detecting disease in seconds of speech
from Strategy& Insider · host Thomas Solbach, Ghioia Irritier, Jan-Philipp Loch
Lara Gervaise and Edoardo Giudice are the co-founders of Virtuosis AI, a start-up pioneering voice biomarker technology. In this episode, they reveal how just 30 seconds of speech can be analyzed to screen for up to 25 health conditions – from Parkinson's and Alzheimer's to depression, anxiety, and cardiometabolic disorders. They share how a chance meeting before generative AI even existed sparked a conviction that voice and AI could transform preventive care at scale. The conversation covers their path from wellness tool to CE-certified medical device, the ethical safeguards behind their workplace integration, what it takes to build health AI in Europe's regulatory environment, and their ultimate vision: a future where monitoring your voice is as routine as tracking your steps, seamlessly embedded into everyday life.
What this episode covers
Lara Gervaise and Edoardo Giudice are the co-founders of Virtuosis AI, a start-up pioneering voice biomarker technology. In this episode, they reveal how just 30 seconds of speech can be analyzed to screen for up to 25 health conditions – from Parkinson's and Alzheimer's to depression, anxiety, and cardiometabolic disorders. They share how a chance meeting before generative AI even existed sparked a conviction that voice and AI could transform preventive care at scale. The conversation covers their path from wellness tool to CE-certified medical device, the ethical safeguards behind their workplace integration, what it takes to build health AI in Europe's regulatory environment, and their ultimate vision: a future where monitoring your voice is as routine as tracking your steps, seamlessly embedded into everyday life.
NOW PLAYING
Strategy& Insider Episode 46 - Detecting disease in seconds of speech
No transcript for this episode yet
Similar Episodes
May 7, 2026 ·8m
Apr 25, 2026 ·9m
Apr 24, 2026 ·5m
Apr 24, 2026 ·9m
Apr 24, 2026 ·11m